首页> 中文学位 >整合素avb6可作为乳腺癌的不良预后因素——中国与孟加拉国的比较研究
【6h】

整合素avb6可作为乳腺癌的不良预后因素——中国与孟加拉国的比较研究

代理获取

目录

声明

INDEX

Synopsis

Acknowledgement

摘要

English Abstract

ABREVIATIONS AND ACRONYMS INDEX

Introduction

SURGICAL ANATOMY OF BREAST

MICROSCOPIC ANATOMY

BREAST DEVELOPMENT AND PHYSIOLOGY

EPIDEMIOLOGY OF BREAST CANCER

Aetological factors

Risk Factors of Breast Cancer

Pathology

Classification of primary Breast Cancer

Non-invasive Epithelial Cancers

Invasive Epithelial Cancers (percentage of total)

Molecular Markers and Breast Cancer Subtypes

Other Tumors of the Breast

DIAGNOSIS OF BREAST DISEASE

Patient History

Physical Examination

Biopsy

BREAST IMAGING

Screening Mammography

Ultrasonography

Magnetic Resonance Imaging

Nonpalpable Mammographic Abnormalities

Wire-Localized Surgical Excision

STAGING oF BREAST CANCER

TNM Classification for Breast Cancer (pathologic Staging)

Management/treatment

Surgery

Axillary surgery

Local recurrence

Radiotherapy

Adjuvant therapy

Hormone therapy

Chemotherapy

Breast reconstruction

Integrin αvβ6

Methods

Clinical samples

Antibodies and IHC

Immunohistochemical analysis and scoring

Statistical analysis

Results

The expression of integrin αvβ6 in breast cancer of China and Bangladesh

Association between clinicopathological characteristics and integrin αvβ6 expression

Correlation of integnn αvβ6 expression and overall sunrival in patients with breast cancer

Discussion

Expression of αvβ6 in Different Cancers

The Role of MMPs in αvβ6 Mediated cancer Progression

αvβ6 Integrin activate of TGF-β

RoIe of αvβ6 Integrin in Epithelial to Mesenchymal Transition

Role of Endocytosis in Cancer Progression

αvβ6 in Therapeutics of Cancer

Discussion result

Conclusion

References

展开▼

摘要

背景:整合素αvβ6在肿瘤的发生发展过程中发挥极为重要的作用。本研究的目的是对比分析整合素αvβ6在中国与孟加拉国乳腺癌标本中的表达情况。
  方法:免疫组化方法检测78例中国患者及42例孟加拉患者的乳腺癌标本及癌旁组织中αvβ6的表达情况,并统计分析其临床意义。
  结果:整合素αvβ6的表达情况与病理组织分级(中国患者组P=0.032,孟加拉患者组P=0.013)、腋淋巴结受累情况(中国患者组P=0.010,孟加拉患者组P=0.001)密切相关。利用Kapl an-Meier检验进行生存分析发现,与整合素α vβ6表达阴性患者相比,整合素αvβ6表达阳性患者中位生存期显著降低(中国患者组P=0.021,孟加拉患者组P=0.002,log-rank检验)。
  结论:在中国与孟加拉国,整合素αvβ6均为乳腺癌浸润与转移的标记物,将来有望成为乳腺癌治疗的靶点。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号